Kunal Kapoor bets on bellies: actor-turned-entrepreneur launches metabolic health platform MetaGO

MUMBAI: Kunal Kapoor has traded crowdfunding for cholesterol. The actor and entrepreneur has launched MetaGO, a doctor-led metabolic health platform aimed squarely at India’s ballooning obesity and diabetes burden, alongside Ketto co-founders Varun Sheth and Zaheer Adenwala.

The trio spent 14 years running Ketto, India’s medical crowdfunding platform, watching families raise money for treatments that, in hindsight, arrived years too late. Type 2 diabetes, cardiovascular disease and obesity rarely appear overnight; they simmer quietly for years before turning into hospital bills. MetaGO is the founders’ bet that intervening earlier, with a doctor rather than a defibrillator, is both cheaper and kinder.

The platform folds doctor consultations, metabolic testing, personalised treatment plans, GLP-1 therapies where clinically warranted, nutrition advice, fitness coaching and ongoing monitoring into a single subscription-style model, rather than a one-off prescription and a pat on the back.

Kapoor does not mince words about the shift. “We’re not building a weight-loss company,” he said. “We’re focused on the years when the right intervention is a doctor’s consultation instead of a surgery.” GLP-1 drugs, he added, have “genuinely changed what’s possible” for people with obesity, but a jab alone is not a strategy. “Nobody should be left alone with a strong drug and a printout,” he said, framing MetaGO’s pitch as helping members “stop fighting their biology alone.”

Sheth, MetaGO’s chief executive, is even more expansive about the ambition. India, he argues, has cracked access to healthcare; the next frontier is making it continuous. “Our ambition is to make the standard of care that was previously available only to a privileged few accessible to every Indian who needs it,” he said, betting that diagnostics, digital care and evidence-based therapies will define healthcare’s next decade.

Backing the sales pitch with clinical weight, cardiologist Dr Kaushal Patel, part of MetaGO’s medical advisory board, noted that GLP-1 therapies work best “combined with proper clinical supervision, metabolic monitoring and sustained lifestyle support” rather than dispensed in isolation.

In practice, every member’s journey begins with a metabolic workup spanning more than 35 biomarkers, followed by a bespoke plan drawn up by an endocrinologist, diabetologist, cardiologist or internal medicine specialist. GLP-1 therapy, when appropriate, sits alongside doctor supervision, nutrition coaching and fitness guidance, with regular check-ins replacing the traditional one-and-done consultation. As members progress, the goalposts shift too, from losing weight to keeping it off.

MetaGO has also dipped a toe into corporate wellness, running a free metabolic health camp for the Mumbai police, complete with blood tests and on-the-spot consultations. More such camps for other professional groups are reportedly in the pipeline.

Whether MetaGO can turn a genuinely important public health problem into a durable business remains to be seen. But with GLP-1 drugs reshaping the economics of obesity care worldwide, and India’s metabolic disease burden climbing fast, Kapoor and company are wagering that the smart money is not in treating the crisis, but in beating it to the punch.